Interestingly, rosiglitazone also decreases the expression of CXCR4 in CAFs, which represent the principal source of stromal cell-derived factor 1 (SDF-1α) production, inhibiting their migratory capabilities and interfering with the autocrine and paracrine signaling loop acting to sustain breast tumor progression [39]. The gene discussed is CXCL12; the disease is breast neoplasm.